Pharma IP Summit: China’s patent linkage system losing steam
A lack of policy direction and timeline on patent linkage is creating industry doubts, but some believe that China shouldn’t rush it forward
While some domestic and foreign drug companies are disappointed with the lack of certainty over a patent linkage system being introduced in China, others think that China shouldn’t rush into implementing such a regime, according to panellists at the 4th...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.